FIG 1.

Schematic representation of the treatments to which the macaques in the present study were subjected following viral load suppression through ART. Chronically SIVmac251-infected macaques were previously treated with a highly intensified ART regimen (i.e., tenofovir, emtricitabine, raltegravir, ritonavir-boosted darunavir, and maraviroc) to suppress viral loads and mimic the condition of HIV-positive individuals under ART (10). Following viral load suppression, auranofin was added to ART, with or without BSO and/or short ART cycles at posttherapy viral rebound (11). These intermittent ART cycles were originally aimed at inducing an immunity against the virus (2, 4) Gray and black arrows indicate, respectively, the timing of BSO administration and of viral rebound following the last treatment suspension.